Journal Article > ReviewFull Text
Curr Opin HIV AIDS. 2017 May 1; Volume 12 (Issue 3); DOI:10.1097/COH.0000000000000370
Easterbrook PJ, Roberts TR, Sands A, Peeling RW
Curr Opin HIV AIDS. 2017 May 1; Volume 12 (Issue 3); DOI:10.1097/COH.0000000000000370
Journal Article > ReviewSubscription Only
Curr Opin HIV AIDS. 2019 January 1; Volume 14 (Issue 1); 21-27.; DOI:10.1097/COH.0000000000000517
Fargher J, Reuter A, Furin J
Curr Opin HIV AIDS. 2019 January 1; Volume 14 (Issue 1); 21-27.; DOI:10.1097/COH.0000000000000517
PURPOSE OF REVIEW
More than two billion people are infected with Mycobacterium tuberculosis and few of them are ever offered therapy in spite of such treatment being associated with reduced rates of morbidity and mortality. This article reviews the current recommendations on the diagnosis and treatment of TB infection (or what is commonly referred to as 'prophylaxis' or 'preventive therapy' of latent TB) and discusses barriers to implementation that have led to low demand for this life-saving therapeutic intervention.
RECENT FINDINGS
Treatment of infection for both TB and drug-resistant TB is well tolerated and effective, and several new, shorter regimens - including rfiapenitine-based regimens of 1 month and 12 weeks duration - have been shown to be effective. Not all persons infected with TB go on to develop disease and the risk is the highest in the first 2 years after infection. Given this, additional work is needed to better identify those at the highest risk of developing active TB.
SUMMARY
Practitioners should offer newer, shorter regimens to persons who are infected with TB and at high risk of developing disease, including people living with HIV and household contacts of people living with TB who are age 5 years and under. This includes individuals who have been exposed to drug-resistant forms of disease. Socioeconomic risk factors may play a key role in the development of TB disease and should also be addressed.
More than two billion people are infected with Mycobacterium tuberculosis and few of them are ever offered therapy in spite of such treatment being associated with reduced rates of morbidity and mortality. This article reviews the current recommendations on the diagnosis and treatment of TB infection (or what is commonly referred to as 'prophylaxis' or 'preventive therapy' of latent TB) and discusses barriers to implementation that have led to low demand for this life-saving therapeutic intervention.
RECENT FINDINGS
Treatment of infection for both TB and drug-resistant TB is well tolerated and effective, and several new, shorter regimens - including rfiapenitine-based regimens of 1 month and 12 weeks duration - have been shown to be effective. Not all persons infected with TB go on to develop disease and the risk is the highest in the first 2 years after infection. Given this, additional work is needed to better identify those at the highest risk of developing active TB.
SUMMARY
Practitioners should offer newer, shorter regimens to persons who are infected with TB and at high risk of developing disease, including people living with HIV and household contacts of people living with TB who are age 5 years and under. This includes individuals who have been exposed to drug-resistant forms of disease. Socioeconomic risk factors may play a key role in the development of TB disease and should also be addressed.
Journal Article > ReviewFull Text
Curr Opin HIV AIDS. 2019 January 1; Volume 14 (Issue 1); DOI:10.1097/COH.0000000000000514
Khwairakpam G, Burry J
Curr Opin HIV AIDS. 2019 January 1; Volume 14 (Issue 1); DOI:10.1097/COH.0000000000000514
With increasing availability of generic direct-acting antivirals (DAAs) and associated price reductions, various governments, multilateral institutions, and donors have started providing testing and treatment for hepatitis C virus (HCV) infection. More data on the quality of these generic medicines and on cost-effectiveness of their use are becoming widely available. This review seeks to describe some of the treatment programs for HCV that are evolving in Cambodia, India, Indonesia, Malaysia, Myanmar, and Thailand.
Journal Article > CommentaryAbstract
Curr Opin HIV AIDS. 2010 January 1; Volume 5 (Issue 1); DOI:10.1097/COH.0b013e3283339b41
Ford NP, Calmy A
Curr Opin HIV AIDS. 2010 January 1; Volume 5 (Issue 1); DOI:10.1097/COH.0b013e3283339b41